The announcement of a public offering often leads to a decrease in the company's stock price in the short term. This is because existing shares are diluted, and investors may sell off their shares due to the perceived overvaluation. In this case, Acumen Pharmaceuticals' announcement of a $100 million underwritten public offering has led to a decrease in its stock price.